SAN FRANCISCO--(BUSINESS WIRE)--June 14, 2006--Bridge Pharmaceuticals, the leading preclinical Contract Research Organization in Asia, announced today that it has recently closed $22,000,000 million Series B round of financing. The investors were returning Series A investors and new venture and investment banking investors from the US.
The capital raised will be used to fund development of its core business and provide for funds for future potential acquisitions in Asia.
About Bridge Pharmaceuticals
Bridge Pharmaceuticals is a US-headquartered company focused on providing cost effective, FDA compliant drug development services in Asia for US, EU and Asian based clients. Bridge is a spin off of SRI International (Stanford Research Institute). Bridge’s Beijing preclinical laboratory will be the first and only US level GLP and AAALAC designed facility in China. Bridge provides complete end-to-end drug development expertise including US IND submissions. The Zhongguancun facility provides services for FDA compliant GLP toxicology, pharmacology, predictive PK/ADMET, safety pharmacology, formulation and other services. Through its Vital Bridge joint venture, Bridge has exclusive access to animal supplies from the largest and only US-franchised (Charles River and Marshall Farms) quality animal breeding facilities in China. Bridge has a division, BridgeNet, which is an unprecedented network of 2500 pre-screened chemical and manufacturing service providers in China and Taiwan, which provides western clients with a single point of contact to access highly qualified and cost effective drug development services in Asia. For more information, visit www.BridgePharmaceuticals.com or call (650) 859-3853.
Copyright © 2005, Bridge Pharmaceuticals, Inc. All rights reserved.
Contact: Bridge Pharmaceuticals Paul Joyce, 650-859-4504 pjoyce@bridgepharmaceuticals.com
Source: Bridge Pharmaceuticals
